Search results
Results from the WOW.Com Content Network
Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. [3] [4] [8] It appears to result in a small benefit in mental function and ability to function. [9] Use, however, has not been shown to change the progression of the disease. [10] Treatment should be stopped if no benefit ...
Memantine/donepezil, sold under the brand name Namzaric among others, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type. [1] It contains memantine , as the hydrochloride, a NMDA receptor antagonist ; and donepezil as the hydrochloride, an acetylcholinesterase inhibitor . [ 1 ]
Aricept – used to slow the progression of Alzheimer's disease Ativan ( lorazepam ) – a benzodiazepine , used to treat anxiety Asendin ( amoxapine ) – an dibenzoxazepine antidepressant
Memantine when added to donepezil in those with moderate-to-severe dementia resulted in "limited improvements" in a 2017 review. [24] The UK National Institute for Clinical Excellence (NICE) issued guidance in 2018 recommending consideration of the combination of memantine with donepezil in those with moderate-to-severe dementia.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Help; Learn to edit; Community portal; Recent changes; Upload file
The Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals, more commonly known by its abbreviation CPS, [1] is a reference book that contains drug monographs and numerous features which help healthcare professionals prescribe and use drugs safely and appropriately.
Paraoxon and rivastigmine are both acetylcholinesterase inhibitors and butyrylcholinesterase inhibitors. [14] [11] [7]In 2015, the United States Food and Drug Administration's Adverse Event Reporting System database compared rivastigmine to the other ChEI drugs donepezil and galantamine found that rivastigmine was associated with a higher frequency of reports of death as an adverse event.
PILLS (Patient Information Language Localisation System) is a one-year effort by the European Commission to produce a prototype tool which will support the creation of various kinds of medical documentation simultaneously in multiple languages, by storing the information in a database and allowing a variety of forms and languages of output.